Tải xuống
Tóm tắt
Background: Polycystic ovary syndrome is the most common endocrine disorder in women of reproductive age. Insulin resistance appears to be a critical factor in PCOS pathogenesis. Metformin, an insulin-sensitizing agent, is thus the preferred treatment option for PCOS. However, no studies on the impact of Metformin on Vietnamese women have been performed. This study aimed to determine the effects of Metformin on the clinical features, endocrine and metabolic profiles in infertile Vietnamese women with PCOS.
Methods: A clinical trial was conducted at the Center for Reproductive Endocrinology and Infertility on infertile women aged 18-40 years old with a diagnosis of PCOS from June 2018 to December 2020. Clinical, endocrine and metabolic characteristics of these patients were assessed before and after 3 months of Metformin treatment. Natural pregnancy rates, side effects and tolerance of Metformin have also been reported.
Results: Among 87 women recruited in this study, the average age was 28.9 ± 3.4 years, 88.5% of women had oligomenorrhea; 18.4% were overweight/obese; and 19.5% of women with PCOS had hirsutism. The most prevalent phenotype of women with PCOS was phenotype D, which accounted for 74.9%. The mean AMH concentration was 7.27 ±3.42 ng/mL. The prevalences of metabolic syndrome and dyslipidemia among PCOS women with infertility were 14.9% and 54%, respectively. After 3 months of Metformin treatment, menstrual regularity was achieved in 30% of patients with oligomenorrhea. Metformin therapy significantly reduced weight and BMI while not impacting the other clinical features, endocrine and metabolic profiles. Side effects have been reported in 19,5% of patients, mainly digestive disorders. Despite this, 100% of women tolerated Metformin and continued treatment. 21.8% of them achieved pregnancy resulting in 14.9% live birth.
Conclusions: 3-month treatment with Metformin for infertile women with PCOS may improve menstrual cycle regularity, weight, BMI, resulting in a clinical pregnancy rate of 21.8% and live birth rate of 14.9%.
Tài liệu tham khảo
Lizneva D, Suturina L, Walker W, Brakta S, GavrilovaJordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertility Sterility. 2016. 106: 6-15.
Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Human reproduction. 2012. 27: 3067-3073.
Palomba S, Infertility in women with polycystic ovary syndrome: pathogenesis and management. 2018: Springer.
Barthelmess EK , Naz RK. Polycystic ovary syndrome: current status and future perspective. Frontiers in bioscience. 2014. 6: 104.
Lim S, Kakoly N, Tan J, Fitzgerald G, Bahri Khomami M, Joham A, et al. Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta‐analysis and meta‐ regression. Obesity reviews. 2019. 20: 339-352.
Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Human reproduction update. 2010. 16: 347- 363.
Bulsara JP, Patel P, Soni A, Acharya S. A review on brief insight into Polycystic Ovarian syndrome. Endocrine Metabolic Science. 2021: 100085.
Lashen H. Role of metformin in the management of polycystic ovary syndrome. Therapeutic advances in endocrinology metabolism. 2010. 1: 117-128.
Velazquez E, Mendoza S, Hamer T, Sosa F, Glueck CJM. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. 1994. 43: 647-654.
Tang T, Lord JM, Norman RJ, Yasmin E, Balen AHJCDoSR. Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. 2012.
Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH. Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews. 2017.
Chou K, von Eye Corleta H, Capp E, Spritzer PJH, research m. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebocontrolled trial. 2003. 35: 86-91.
Eisenhardt S, Schwarzmann N, Henschel V, Germeyer A, Von Wolff M, Hamann A, et al. Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial. 2006. 91: 946-952.
Hoeger KM, Kochman L, Wixom N, Craig K, Miller RK, Guzick DSJF, et al. A randomized, 48-week, placebocontrolled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. 2004. 82: 421-429.
Pasquali R. Metabolic syndrome in polycystic ovary syndrome. Metabolic Syndrome Consequent to Endocrine Disorders. 2018. 49: 114-130.
Peigné M , Dewailly D. Long term complications of polycystic ovary syndrome (PCOS). in Annales d’endocrinologie. 2014. Elsevier.
Le MT, Nguyen VQH, Truong QV, Le DD, Le VNS, Cao NTJE, et al. Metabolic syndrome and insulin resistance syndrome among infertile women with polycystic ovary syndrome: a cross-sectional study from Central Vietnam. 2018. 33: 447-458.
Cao NT, Le MT, Nguyen VQH, Pilgrim J, Le VNS, Le DD, et al. Defining polycystic ovary syndrome phenotype in Vietnamese women. Journal of Obstetrics Gynaecology Research. 2019. 45: 2209-2219.
Zhang H, Zhu F, Xiong J, Shi X, Fu SJBAIJoO, Gynaecology. Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large‐scale Chinese population. 2009. 116: 1633-1639.
ESHRE TR , Group A-SPCW. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility Sterility. 2004. 81: 19-25.
Huang Z , Yong E-L. Ethnic differences: is there an Asian phenotype for polycystic ovarian syndrome? Best practice research Clinical obstetrics gynaecology. 2016. 37: 46-55.
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute scientific statement. 2005. 112: 2735-2752.
Health NIo. Evidence-based methodology workshop on polycystic ovary syndrome. National Institutes of Health: Bethesda, MD, USA. 2012: 1-14.
Lê Quỳnh Trang LMT. Rối loạn chuyển hóa lipid ở bệnh nhân vô sinh có hội chứng buồng trứng đa nang. Tạp chí phụ sản. 2019. 17: 48 -53.
Lê Minh Tâm LVH, Nguyễn Thị Phương Lê, Lê Đình Dương, Lê Viết Nguyên Sa và cộng sự. Rối loạn nội tiết sinh sản ở bệnh nhân vô sinh có hội chứng buồng trứng đa nang. Tạp chí phụ sản. 2017. 15: 119-125.
Lê Viết Nguyên Sa TTNQ, Lê Minh Tâm, Cao Ngọc Thành. Ảnh hưởng của các kiểu hình Hội chứng buồng trứng đa nang khác nhau lên kết quả thụ tinh trong ống nghiệp. Tạp chí phụ sản. 2021. 19: 54 -60.
Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. 2000. 85: 2767-2774.
Guan Y, Wang D, Bu H, Zhao T, Wang HJIjoe. The effect of metformin on polycystic ovary syndrome in overweight women: a systematic review and meta-analysis of randomized controlled trials. 2020. 2020.
Trolle B, Flyvbjerg A, Kesmodel U, Lauszus FJHR. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. 2007. 22: 2967-2973.
Yang P-K, Hsu C-Y, Chen M-J, Lai M-Y, Li Z-R, Chen C-H, et al. The efficacy of 24-month metformin for improving menses, hormones, and metabolic profiles in polycystic ovary syndrome. 2018. 103: 890-899.
Swathi A , Reddy YJB. Effect of Metformin therapy on lipid profile in obese and non-obese women with polycystic ovarian syndrome (PCOS). 2022. 42: 134-137.
Lord JM, Flight IH, Norman RJJB. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. 2003. 327: 951.
Sharpe A, Morley LC, Tang T, Norman RJ, Balen AH. Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews. 2019.
| Đã xuất bản | 05-01-2025 | |
| Toàn văn |
|
|
| Ngôn ngữ |
|
|
| Số tạp chí | Số 83 (2022) | |
| Phân mục | Nghiên cứu | |
| DOI | 10.38103/jcmhch.83.9 | |
| Từ khóa | PCOS, Metformin, Endocrine, Metabolic, Menstrual cycle, Pregnancy |
công trình này được cấp phép theo Creative Commons Attribution-phi thương mại-NoDerivatives 4.0 License International .
Bản quyền (c) 2022 Tạp chí Y học lâm sàng Bệnh viện Trung Ương Huế